Plus Therapeutics Gets DSMB Approval To Start Eighth Cohort For Glioblastoma Trial

by Vandana Singh, Benzinga Editor

June 16, 2021 8:29 AM | 1 min read |

The Data and Safety Monitoring Board has recommended Plus Therapeutics Inc PSTV to proceed to the eighth cohort of Phase 1 dose-escalation ReSPECT trial evaluating Rhenium NanoLiposome (RNL) for recurrent glioblastoma.
The eighth cohort of the ReSPECT trial will implement a 40% increase in total radioactivity.
The planned infused dose will be 31.2 millicuries in a volume of 12.3 milliliters (increased from 22.3 millicuries and 8.8 milliliters, respectively, used in cohort seven).
The planned maximum flow rate will not change.
Price Action: PSTV shares are higher by 2.94% at $2.80 during the premarket session on the last check Wednesday.